Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TSE:4570'
s PB Ratio Range Over the Past 10 Years
Min: 1.66 Med: 3.05 Max: 19.19
Current: 4.95
During the past 13 years, Immuno-Biological Laboratories Co's highest PB Ratio was 19.19. The lowest was 1.66. And the median was 3.05.
TSE:4570's PB Ratio is ranked worse than 69.49% of 1229
companies
in the Biotechnology industry
Industry Median: 2.82
vs TSE:4570: 4.95
During the past 12 months, Immuno-Biological Laboratories Co's average Book Value Per Share Growth Rate was 21.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 19.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 3.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -6.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Immuno-Biological Laboratories Co was 19.60% per year. The lowest was -24.70% per year. And the median was -6.20% per year.
Back to Basics: PB Ratio
Immuno-Biological Laboratories Co (TSE:4570) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Immuno-Biological Laboratories Co PB Ratio Related Terms
Immuno-Biological Laboratories Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Immuno-Biological Laboratories Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immuno-Biological Laboratories Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immuno-Biological Laboratories Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Immuno-Biological Laboratories Co's PB Ratio falls into.
Immuno-Biological Laboratories Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Immuno-Biological Laboratories Co (TSE:4570) has a PB Ratio of 4.95 as of Jul. 22, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Immuno-Biological Laboratories Co and its competitors. This is 62% above median its historical median of 3.05. Over the past decade, Immuno-Biological Laboratories Co's PB Ratio has ranged from 1.66 to 19.19. According to the industry distribution chart, Immuno-Biological Laboratories Co ranks #854 out of 1229 companies in the Biotechnology industry, placing it in the top 69.5%.
Is Immuno-Biological Laboratories Co's PB Ratio too high?
Immuno-Biological Laboratories Co's current PB Ratio of 4.95 is 62% above median its 10-year median of 3.05. Over the past 10 years, this metric has ranged from a low of 1.66 to a high of 19.19. The Biotechnology industry median PB Ratio is 2.82. Immuno-Biological Laboratories Co's value of 4.95 is 75.5% above this industry median. Based on the distribution chart, Immuno-Biological Laboratories Co ranks #854 out of 1229 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Immuno-Biological Laboratories Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immuno-Biological Laboratories Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immuno-Biological Laboratories Co ranks #854 out of 1229 companies for PB Ratio. This places Immuno-Biological Laboratories Co in the lower half of its industry. The industry median PB Ratio is 2.82. Immuno-Biological Laboratories Co's value of 4.95 is 75.5% above this benchmark. Historically, Immuno-Biological Laboratories Co's own PB Ratio has ranged from 1.66 to 19.19 over the past decade. While the company's 10-year median is 3.05 vs. the industry median of 2.82, Immuno-Biological Laboratories Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immuno-Biological Laboratories Co's current PB Ratio of 4.95 is 75.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Immuno-Biological Laboratories Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immuno-Biological Laboratories Co's current PB Ratio is 4.95, which is 62% above median its own 10-year median of 3.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuno-Biological Laboratories Co stock overvalued right now?
Based on GuruFocus' analysis, Immuno-Biological Laboratories Co (TSE:4570) is currently considered Significantly Overvalued. The stock's GF Value™ is 円579.93, compared to a current price of 円980.00 — trading 69% above its estimated fair value. The current PB Ratio is 4.95, which is 62% above median its 10-year median of 3.05 and 75.5% above the Biotechnology industry median of 2.82. Immuno-Biological Laboratories Co's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Immuno-Biological Laboratories Co (TSE:4570), the current PB Ratio is 4.95 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immuno-Biological Laboratories Co (TSE:4570) Overvalued in 2026?
Based on GuruFocus' analysis, Immuno-Biological Laboratories Co stock appears to be overvalued.
The current stock price of 円980.00 is trading 69% above its estimated GF Value™ of 円579.93.
GuruFocus considers Immuno-Biological Laboratories Co to be Significantly Overvalued.
Key valuation signals for TSE:4570:
PB Ratio: 4.95 (62% above median its 10-year median of 3.05)
GF Value™: 円579.93 vs. price of 円980.00 (69% above fair value)
Industry Position: 75.5% above the Biotechnology median (#854 of 1229)
No single metric tells the full story. See the TSE:4570 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immuno-Biological Laboratories Co Business Description
Immuno-Biological Laboratories Co Ltd focuses on research and development. It researches, develops, manufacture and supplies various immunological research reagents, and customized services. It is engaged in research and development of materials used in diagnostic products and valuable seeds and technology for protein production using transgenic silkworm cocoons, which make it possible to create valuable proteins as well as antibodies. It works on clinical reagents for cancer research. Its research scientists are producing inflammatory cytokines, growth factors & antibodies for use against these cancers.
58GF Score
Get the complete analysis for TSE:4570
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4570 has been successfully added to your 
